[HTML][HTML] P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated …
T Tamura, Y Nishiwaki, K Watanabe, K Nakagawa… - Journal of Thoracic …, 2007 - jto.org
Background: Erlotinib is a selective epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). We conducted two phase II studies (JO16565 and JO18396) of …
inhibitor (EGFR-TKI). We conducted two phase II studies (JO16565 and JO18396) of …
[引用][C] P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated …
T Tamura, Y Nishiwaki, K Watanabe… - Journal of Thoracic …, 2007 - cir.nii.ac.jp
P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients
with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese …
with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese …
[引用][C] Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of …
T TAMURA - J Thorac Oncol, 2007 - cir.nii.ac.jp
Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with
advanced non-small cell lung cancer (NSCLC) ; integrated analysis of two Japanese phase II …
advanced non-small cell lung cancer (NSCLC) ; integrated analysis of two Japanese phase II …